Marco Falasca
In recent years, spectacular advances in understanding of molecular mechanism of cancer progression have revolutionized the way we see the process of malignant transformation and we are waiting for this knowledge to be translate in better treatments for cancer patients. This progress has attracted the interest towards the development of targeted therapies for cancer and creates the basis for the so called “personalized medicine”. However, this advancement has not been paralleled by discoveries in the field of biological indicators, or molecular biomarkers, able to implement the targeted therapies.
Teile diesen Artikel